Literature DB >> 28621630

Evaluation of surgical treatment for neuropathic pain from neuroma in patients with injured peripheral nerves.

Valérie Decrouy-Duruz, Thierry Christen, Wassim Raffoul.   

Abstract

OBJECTIVE Chronic neuropathic pain after peripheral nerve injury is a major clinical problem. Its management is difficult, and therapeutic approaches vary and include oral medication, neurostimulation, and surgery. The aim of this study was to assess the adequacy of surgical nerve revision in a large series of patients with long-term follow-up. METHODS The authors reviewed the charts of 231 patients (335 nerve injuries) who experienced neuropathic pain after peripheral nerve injury and underwent surgery for nerve revision at the authors' institution between 1997 and 2012. The following parameters were recorded for each patient: history, location, duration, and severity of the pain and details of nerve revision surgery. In addition, patients were invited to participate in a follow-up consultation and were asked to score their pain at that time. Current medications and examination findings were also documented. RESULTS Elective surgery was the source of nerve injury for 55.4% of the patients. The lower extremity was the most commonly involved anatomical region (54.3%), followed by the lower abdomen (16.4%) and the thoracic region (13%). The mean time between the onset of injury and revision surgery was 48 months. On average, 1.3 injured nerves per patient were explored, and surgery was performed 1.2 times per patient. Each nerve underwent revision 1.1 times on average. Neuromas-in-continuity and scar-tethered nerves were observed in 205 nerves (61%) and terminal neuromas were observed in 130 nerves (39%). The authors performed 186 (56%) neurolyses and 149 (44%) neuroma resections and translocations. The mean follow-up of the 127 (55%) patients who agreed to come back for a consultation was 68 months. These patients indicated an average pain decrease of 4 points in the visual analog scale (VAS) score. Pain relief greater than a 2-point decrease on the VAS, a criterion for a successful treatment according to the European Federation of Neurological Societies guidelines, was encountered in 80% of patients. Pain relief did not vary in a statistically significant way with regard to surgical technique, age and sex of the patient, affected nerve, or time between trauma and surgery. Before surgery, 76% of the patients were on a regimen of paracetamol and/or NSAIDs and 44% received opiates, while after nerve revision only 37% still required simple analgesia and 14% needed opiates. CONCLUSIONS Bearing in mind that medication achieves satisfying pain relief in only 30%-40% of patients with neuropathic pain, surgery must be considered as an effective alternative therapy. No objective criteria were shown to be factors of poor prognosis. Systematic preoperative clinical mapping of the injured nerves and diagnostic nerve blocks could improve the primary success rate of the surgery.

Entities:  

Keywords:  VAS = visual analog scale; neurolysis; neuroma; neuropathic pain; peripheral nerve injury; surgical management

Mesh:

Year:  2017        PMID: 28621630     DOI: 10.3171/2017.1.JNS161778

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

1.  Reversal of neuropathic pain is associated with corticostriatal functional reorganization after nerve repair in the spared nerve injury model.

Authors:  Qi-Yuan Bao; Pei-Ching Chang; Maria Virginia Centeno; Melissa A Farmer; Marwan Baliki; Daniel Procissi; Weibin Zhang; A Vania Apkarian
Journal:  Pain       Date:  2022-01-25       Impact factor: 7.926

2.  Chronic Nerve Injuries and Delays in Surgical Treatment Negatively Impact Patient-reported Quality of Life.

Authors:  John M Felder; Ivica Ducic
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-05-21

3.  Clinical Outcomes of Symptomatic Neuroma Resection and Reconstruction with Processed Nerve Allograft.

Authors:  Sonu A Jain; Jason Nydick; Fraser Leversedge; Dominic Power; Joseph Styron; Bauback Safa; Gregory Buncke
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-10-04

4.  Impact of Nerve Surgery on Opioid and Medication Use in Patients with Chronic Nerve Injuries.

Authors:  John M Felder; Ivica Ducic
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-09-07

5.  Surgically Treated Neuroma in Upper Extremity: Patient Characteristics and Factors Influencing Outcome of Surgery.

Authors:  Erika Nyman; Emma Dahlin; Hanna Gudinge; Lars B Dahlin
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-01-31

Review 6.  Revision Peripheral Nerve Surgery of the Upper Extremity.

Authors:  Rami P Dibbs; Kausar Ali; Shayan M Sarrami; John C Koshy
Journal:  Semin Plast Surg       Date:  2021-06-08       Impact factor: 2.314

7.  Evaluation of postoperative outcomes in patients following multi-level surgical reconstructions with the use Avive soft tissue membrane on nerve after traumatic injury of the upper extremity and lower extremity.

Authors:  Cameron T Cox; Joash R Suryavanshi; Bradley O Osemwengie; Sterling Rosqvist; Matthew Blue; Desirae McKee; Brendan J MacKay
Journal:  SAGE Open Med       Date:  2021-06-06

8.  Nerve wrap after end-to-end and tension-free neurorrhaphy attenuates neuropathic pain: A prospective study based on cohorts of digit replantation.

Authors:  Xiaozhong Zhu; Haifeng Wei; Hongyi Zhu
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

9.  Treatment of Neuroma-induced Chronic Pain and Management of Nerve Defects with Processed Nerve Allografts.

Authors:  Ivica Ducic; Joshua Yoon; Kyle R Eberlin
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-12-19

10.  Impaired Limb Functional Outcome of Peripheral Nerve Regeneration Is Marked by Incomplete Recovery of Paw Muscle Atrophy and Brain Functional Connectivity in a Rat Forearm Nerve Repair Model.

Authors:  Qiyuan Bao; Qi Liu; Jun Wang; Yuhui Shen; Weibin Zhang
Journal:  Neural Plast       Date:  2021-02-11       Impact factor: 3.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.